Wednesday, September 26, 2012

GlaxoSmithKline files ICS/LABA combination (Biranteroru) for approval in Japan

Biranteroru is a once daily LABA/ICS combination and comprises vilanterol(LABA) and
fluticasone furoate(ICS). If approved, Biranteroru would be the first once daily ICS/LABA combination to reach the market. Biranteroru is a follow on version of GSK's existing drug Advair (twice daily ICS/LABA combination).